Product Description
Finasteride is an FDA-approved pharmacologic agent for treating benign prostate hyperplasia and androgenic alopecia (male pattern hair loss) in men. Finasteride has also been used to treat signs of hyperandrogenism, such as hirsutism, and may be used in transgender women in combination with estrogen for its anti-androgen properties. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK513329/)
Mechanisms of Action: 5AR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Alopecia | Prostatic Hyperplasia
Known Adverse Events: Erectile Dysfunction | Back Pain | Headache | Pain Unspecified | Myalgia | Dyspepsia | Flushing
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Brazil
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Alopecia Areata|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IP4- CHRONOS | P3 |
Unknown status |
Prostate Cancer |
2027-07-25 |
|
| EMS2119 - FINLÂNDIA | P3 |
Recruiting |
Alopecia Areata |
2025-04-01 |
55% |
| EMS2119 - FINLÂNDIA | P3 |
Recruiting |
Alopecia Areata |
2025-04-01 |
55% |